REGISTER FOR SOSV’s VC-Founder Therapeutics Matchup July 13-17

Tinkeso Therapeutics

Cell therapy for oncology and autoimmune diseases.

Company details

Novel allogeneic Natural Killer T (NKT) cell therapies for oncology and autoimmune diseases.

The global oncology drugs market is expected to grow from $231 billion in 2024 to over $532 billion in 2031, driven by demand for more targeted therapies.

Tinkeso Therapeutics Quote Image
Emmie Fan, Co-Founder and CEO of Tinkeso Therapeutics
The human immune system has a greater ability to fight off cancer and autoimmune diseases than we realize. With natural killer T (NKT) therapies, Tinkeso is harnessing that ability for patients with some of the most difficult-to-treat cancers.

Team

Emmie Fan

CEO

Jerry Zhou

CSO

Get In Touch with Tinkeso Therapeutics

Please tell us a little bit about yourself and why you'd like to get connected. Tinkeso Therapeutics + SOSV will follow up with you via email.

This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.